Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, collaborated with scientists from the University of British Columbia to develop lipid nanoparticle systems using the NanoAssemblr technology. This work has been recently published in the journal, Langmuir (2012, 28 (7): 3633-3640). The article “Bottom-Up Design and Synthesis of Limit Size Lipid Nanoparticle Systems with Aqueous and Triglyceride Cores Using Millisecond Microfluidic Mixing” describes the development of “limit-size” systems (the smallest achieveable aggregates compatible with the packing of the molecular constiuents in a defined and energetically stable structure) with either polar, or non-polar cores. Liposome systems (polar core) comprising POPC, or POPC and cholesterol could be manufactured at limit sizes of 20 nm and 40 nm, respectively. Further, these systems were amenable to pH gradient-mediated  encapsulation of the anti-cancer drug, doxorubicin. Non-polar systems (nanoemulsions) formulated with the triglyceride triolein and the phospholipid POPC could be readily manipulated to vary particle size in the range 20 nm – 50 nm. To our knowledge this is the first report of stable triglyceride emulsions in this size range generated by a scalable manufacturing process.

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.